Photodynamic therapy for the treatment of squamous cell carcinoma using benzoporphyrin derivative.
BACKGROUND
Photodynamic therapy (PDT) involves laser light excitation of a tumor-localizing photosensitizer to destroy neoplasms. Benzoporphyrin derivative (BPD) is a new photosensitizer with several favorable characteristics.


OBJECTIVE
Studies were designed to: 1) assess the efficacy of BPD-mediated PDT in treating in vivo squamous cell carcinomas (SCC); 2) obtain dosimetry data for BPD and laser parameters; and 3) establish clinical and histologic correlates of BPD-induced tumor regression.


METHODS
Human SCC was implanted into nude mice. One group received BPD followed by laser light of 150 J/cm2 from an argon-pumped dye laser at 690 nm. Three control groups included laser energy alone, BPD alone, and no treatment.


RESULTS
At day 21 posttreatment only PDT-treated tumors showed a statistically significant decrease in tumor volume and complete cure rate. Clinical resolution (scar) correlated perfectly with histologic resolution (scar).


CONCLUSIONS
Human SCC in a nude mouse model responds to BPD-mediated PDT.
Division of Dermatology, UCLA Medical Center, Los Angeles, California 90024.
J
J
Marcus
E
E
Glassberg
L
L
Dimino-Emme
R
R
Yamamoto
R L
RL
Moy
S G
SG
Vari
T
T
Papaioannou
V R
VR
Pergadia
W J
WJ
Snyder
W S
WS
Grundfest
D000708:Anaplasia; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002467:Cell Nucleus / Q000648:ultrastructure; D002921:Cicatrix / Q000473:pathology; D006801:Humans; D053685:Laser Therapy; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009361:Neoplasm Invasiveness; D010778:Photochemotherapy; D011166:Porphyrins / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014407:Tumor Cells, Cultured
D011166:Porphyrins; D011838:Radiation-Sensitizing Agents; C504224:benzoporphyrin D